Prakash Ramachandran
Overview
Explore the profile of Prakash Ramachandran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2816
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767
Ramachandran P, Brice M, Sutherland E, Hoy A, Papachristoforou E, Jia L, et al.
Hepatol Commun
. 2024 Nov;
8(12).
PMID: 39585303
Background: The farnesoid X receptor (FXR) is a leading therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH)-related fibrosis. INT-767, a potent FXR agonist, has shown promise in preclinical models. We aimed...
3.
4.
Booijink R, Ramachandran P, Bansal R
Trends Pharmacol Sci
. 2024 Jun;
45(7):614-627.
PMID: 38853100
Growing evidence suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) is significantly higher in men versus women. Increased prevalence is observed in postmenopausal women, suggesting that age and sex (hormones)...
5.
Patir A, Barrington J, Szymkowiak S, Brezzo G, Straus D, Alfieri A, et al.
Cell Rep
. 2024 May;
43(5):114250.
PMID: 38762882
Acute stroke triggers extensive changes to myeloid immune cell populations in the brain that may be targets for limiting brain damage and enhancing repair. Immunomodulatory approaches will be most effective...
6.
Colella F, Ramachandran P
J Hepatol
. 2023 Dec;
80(3):390-393.
PMID: 38122832
No abstract available.
7.
Kendall T, Jimenez-Ramos M, Turner F, Ramachandran P, Minnier J, McColgan M, et al.
Nat Med
. 2023 Oct;
29(11):2939-2953.
PMID: 37903863
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause of chronic liver disease worldwide and represents an unmet precision medicine challenge. We established a retrospective national cohort of 940...
8.
Bhattacharya M, Ramachandran P
Nat Immunol
. 2023 Jul;
24(9):1423-1433.
PMID: 37474654
Fibrosis, defined by the excess deposition of structural and matricellular proteins in the extracellular space, underlies tissue dysfunction in multiple chronic diseases. Approved antifibrotics have proven modest in efficacy, and...
9.
Kotsiliti E, Leone V, Schuehle S, Govaere O, Li H, Wolf M, et al.
J Hepatol
. 2023 May;
79(2):296-313.
PMID: 37224925
Background & Aims: The progression of non-alcoholic steatohepatitis (NASH) to fibrosis and hepatocellular carcinoma (HCC) is aggravated by auto-aggressive T cells. The gut-liver axis contributes to NASH, but the mechanisms...
10.
Li X, Selli C, Zhou H, Cao J, Wu S, Ma R, et al.
J Exp Med
. 2023 Feb;
220(4).
PMID: 36749798
Metastatic castration-resistant prostate cancer (PC) is the final stage of PC that acquires resistance to androgen deprivation therapies (ADT). Despite progresses in understanding of disease mechanisms, the specific contribution of...